Tuesday, January 17, 2012

Genentech commits $95M to Constellation Pharma epigenetics, chromatin programs

Genentech Inc. will pump $95 million into Constellation Pharmaceuticals Inc., a company focused on epigenetics and chromatin in cancer and other diseases.
Epigenetic research focuses on changes in gene expression that can be passed on to the next generation but do not change underlying gene sequences. Chromatin is the combination of DNA and proteins in the nucleus of a cell.
Under terms of the deal, Genentech committed funding of $95 million, including an upfront payment and research funding over three years. Constellation will be eligible for development and commercialization milestone payments as well as up to double-digit royalties on commercial sales of products taken to market by Genentech.

No comments:

Post a Comment